Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|
| Revenue | $259K | $184K | $450K | $536K |
| Revenue growth | — | -29.0% | 144.2% | 19.3% |
| Operating income | -$1.92M | -$2.59M | -$4.75M | -$5.08M |
| Operating margin | -738.7% | -1406.3% | -1055.6% | -947.2% |
| Net income | -$1.87M | -$2.60M | -$4.62M | -$5.02M |
| Net margin | -719.3% | -1410.6% | -1027.3% | -935.2% |
| EPS (diluted) | -$0.55 | -$0.64 | -$6.16 | -$4.79 |
| Fiscal year | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|
| Operating cash flow | -$989K | -$1.83M | -$3.15M | -$3.95M |
| Capital expenditures | — | — | $14.4K | — |
| Free cash flow | — | — | -$3.16M | — |
| Fiscal year | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|
| Cash & equivalents | $1.41M | $5.12M | $3.29M | $2.18M |
| Total assets | $2.01M | $5.95M | $3.58M | $2.67M |
| Total liabilities | $589K | $1.27M | $433K | $754K |
| Shareholders' equity | $1.42M | $4.68M | $3.14M | $1.92M |
| Retained earnings | -$3.11M | -$5.70M | -$10.3M | -$15.3M |
| Shares (wtd avg diluted) | 3.41M | 4.06M | 750K | 1.05M |
Every figure is extracted from LIPELLA PHARMACEUTICALS INC.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.